IN8bio Future Growth

Future criteria checks 0/6

IN8bio is forecast to grow revenue at 73.6% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	36.2%
Revenue growth rate	73.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

MUN:6JH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	N/A	N/A	N/A	N/A	2
12/31/2023	N/A	N/A	N/A	N/A	3
12/31/2022	N/A	N/A	N/A	N/A	3
9/30/2022	N/A	-27	-21	-18	N/A
6/30/2022	N/A	-21	-20	-19	N/A
3/31/2022	N/A	-18	-16	-16	N/A
12/31/2021	N/A	-15	-14	-14	N/A
9/30/2021	N/A	-12	-13	-13	N/A
6/30/2021	N/A	-11	-9	-9	N/A
3/31/2021	N/A	-11	-8	-8	N/A
12/31/2020	N/A	-10	-7	-7	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-6	-6	N/A
3/31/2020	N/A	-6	-6	-5	N/A
12/31/2019	N/A	-6	-5	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6JH's forecast earnings growth is above the savings rate (0.03%).

Earnings vs Market: Insufficient data to determine if 6JH's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if 6JH's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 6JH is forecast to have no revenue next year.

High Growth Revenue: 6JH is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 6JH's Return on Equity is forecast to be high in 3 years time

IN8bio Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

IN8bio, Inc. announced that it expects to receive $14.442298 million in funding

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies